Wire · opportunities
Cancer Vaccine Platform Uses COVID-19 Immune Memory to Fight Tumors
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
Celloram's PROTEXI platform redirects pre-existing COVID-19 immune memory to enhance cancer vaccine efficacy, showing improved tumor control and survival in preclinical melanoma and breast cancer models. First-in-human trials in sarcoma patients are now planned.
This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Celloram has moved from preclinical proof to first-in-human trials with a cancer vaccine mechanism that now works in immune-cold tumours, opening sarcoma and other resistant cancers to checkpoint inhibitor combinations. Your immunotherapy partner just got a new clinical asset with a validated helper T-cell signal — if you supply adjuvants, assays, or manufacturing, this trial scales to multiple indications.
◆ Related on Wire
◆ Topics